FierceBiotech 2026-02-19 Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
FierceBiotech 2026-02-19 J&J halts enrollment in phase 2 trial of AC Immune-partnered Alzheimer's therapy
FierceBiotech 2026-02-19 GSK strikes 5-year deal with Jackson Laboratory focused on neurodegenerative disease research
FierceBiotech 2026-02-19 NIH Director Jay Bhattacharya to take over as temporary CDC chief: media reports
FierceBiotech 2026-02-18 Blood from pediatricians yields potential new medicines for respiratory viruses
FierceBiotech 2026-02-18 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
FierceBiotech 2026-02-18 Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
FierceBiotech 2026-02-18 Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
FierceBiotech 2026-02-18 Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
FierceBiotech 2026-02-18 Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
FierceBiotech 2026-02-18 Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
FierceBiotech 2026-02-17 Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering